Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 25, 2022
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
Journal: Orphanet journal of rare diseases
Published: October 06, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©.
Journal: Orphanet journal of rare diseases
Published: May 26, 2021
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.
Journal: Orphanet journal of rare diseases
Published: May 21, 2021
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Journal: Leukemia research
Published: December 14, 2020
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 29, 2015
Ceritinib in ALK-rearranged non-small-cell lung cancer.
Journal: The New England journal of medicine
Published: March 28, 2014
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 27, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026